The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy
Frontiers in Oncology · 05.06.2024 · 14
DOI: 10.3389/fonc.2024.1384600 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 05.06.2024. Verfasst von Ryan Jacobs und 1 weiteren Autor:innen. Beteiligte Einrichtung: Levine Cancer Institute, Charlotte, NC, United States. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Significant unmet need remains for patients with relapsed/refractory FL after ≥3 lines of prior therapy. While recent advancements have likely improved the survival of patients with FL, most patients will eventually relapse. The treatment of patients with FL after multiple relapses or those with refractory disease has historically led to lower overall response rates (ORR) and shorter progression-free survival (PFS) with each subsequent line of therapy. New treatments with high ORR and durable PFS are needed in this setting, particularly in patients that progress within 2 years of first line chemoimmunotherapy (POD24) and/or those refractory chemoimmunotherapy. Chimeric antigen receptor T-cell therapies targeting the B-cell antigen CD-19 have shown to be an efficacious treatment option for both heavily pretreated patients and/or patients with refractory FL, resulting in a high ORR and durable remissions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Levine Cancer Institute, Charlotte, NC, United States.
- Dana-Farber Cancer Institute, Boston, MA, United States.
Zitieren
APA
Jacobs, R., & Jacobson, C. (2024). The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1384600
Vancouver
Jacobs R, Jacobson C. The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy. Frontiers in Oncology. 2024;14. doi:10.3389/fonc.2024.1384600
BibTeX
@article{Jacobs2024,
author = {Jacobs, Ryan and Jacobson, Caron},
title = {The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy},
journal = {Frontiers in Oncology},
year = {2024},
volume = {14},
doi = {10.3389/fonc.2024.1384600}
}
EUVIMED